Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7?36 amide] in the fasting state in healthy subjects

GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN

Bernhard Kreymann, Mohammad A. Ghatei, Gareth Williams et al. · The Lancet · 1987 · 1.9K citations

Life Sciences, Endocrinology, Physiology +10

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.

Michael A. Nauck, Markus M. Heimesaat, Jens J. Holst et al. · Journal of Clinical Investigation · 1993 · 1.6K citations · Full text

Medicine, Endocrinology, Pharmacology +15

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients

Michael A. Nauck, N. Kleine, C. �rskov et al. · Diabetologia · 1993 · 1.1K citations · Full text

Medicine, Endocrinology, Internal Medicine +15

Antidiabetogenic Effect of Glucagon-like Peptide-1 (7–36)amide in Normal Subjects and Patients with Diabetes Mellitus

M. Gutniak, Jens J. Holst, Bo Åhrén et al. · New England Journal of Medicine · 1992 · 875 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man

A. Wettergren, Birgit Schjoldager, Poul Erik Mortensen et al. · Digestive Diseases and Sciences · 1993 · 676 citations

Medicine, Endocrinology, Pharmacology +12